Results 11 to 20 of about 2,532,507 (339)

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer.

New England Journal of Medicine, 2021
BACKGROUND Treatment for patients with recurrent ovarian cancer has been mainly based on systemic therapy. The role of secondary cytoreductive surgery is unclear.
P. Harter, J. Sehouli, I. Vergote, G. Ferron, A. Reuss, W. Meier, S. Greggi, Berit J. Mosgard, F. Selle, F. Guyon, C. Pomel, F. Lécuru, R. Zang, E. Åvall-Lundqvist, Jae-weon Kim, J. Ponce, F. Raspagliesi, G. Kristensen, J. Classe, P. Hillemanns, P. Jensen, A. Hasenburg, S. Ghaem-Maghami, M. Mirza, B. Lund, A. Reinthaller, A. Santaballa, A. Olaitan, F. Hilpert, A. du Bois   +29 more
semanticscholar   +1 more source

Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin

Nature Communications, 2022
In patients with colorectal peritoneal metastases scheduled for cytoreductive surgery, accurate preoperative estimation of tumor burden and subsequent intraoperative detection of all tumor deposits remains challenging.
J. D. de Gooyer, F. M. Elekonawo, A. Bremers, O. Boerman, E. Aarntzen, P. D. de Reuver, I. Nagtegaal, M. Rijpkema, J. D. de Wilt   +8 more
semanticscholar   +1 more source

Cytoreductive surgery in ovarian cancer [PDF]

Cancer Imaging, 2007
As the overall prognosis for patients with ovarian cancer is poor, the management of this condition should be restricted to expert multi-disciplinary teams in gynaecological oncology. Apparent early stage ovarian cancer requires accurate and complete staging so that potential sites for metastases are not missed.
Arjun R. Jeyarajah, Christophe Pomel, David E. Oram, David A Milliken, K. Reynolds, Jacques Dauplat, John A. Shepherd   +6 more
openaire   +3 more sources

Factors predicting postoperative morbidity after cytoreductive surgery for ovarian cancer: a systematic review and meta-analysis

Journal of Gynecologic Oncology, 2022
Objective Advances in ovarian cancer cytoreductive surgery have enabled more extensive procedures to achieve maximal cytoreduction but with a consequent increase in postoperative morbidity and mortality.
M. Kengsakul, G. N. Nieuwenhuyzen-de Boer, S. Udomkarnjananun, S. J. Kerr, C. Niehot, Helene J van Beekhuizen   +5 more
semanticscholar   +1 more source

The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery.

JAMA Surgery, 2021
Importance Studies on the prognostic role of hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei (PMP) are currently not available.
S. Kusamura, F. Barretta, Y. Yonemura, P. Sugarbaker, B. Moran, E. Levine, D. Goéré, D. Baratti, E. Nizri, D. Morris, O. Glehen, A. Sardi, P. Barrios, F. Quénet, L. Villeneuve, A. Gómez-Portilla, I. D. de Hingh, W. Ceelen, J. Pelz, P. Piso, S. González-Moreno, K. van der Speeten, M. Deraco   +22 more
semanticscholar   +1 more source

A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer. [PDF]

PLoS ONE, 2017
OBJECTIVE:Postoperative residual tumor is the major prognostic factor in ovarian cancer. The feasibility of complete cytoreductive surgery is assessed by laparoscopy.
Marion Chesnais, Fabrice Lecuru, Myriam Mimouni, Charlotte Ngo, Arnaud Fauconnier, Cyrille Huchon   +5 more
doaj   +1 more source

Development and Validation of an Explainable Machine Learning Model for Major Complications After Cytoreductive Surgery

JAMA Network Open, 2022
Key Points Question Can machine learning provide superior risk prediction compared with the current statistical methods for patients undergoing cytoreductive surgery?
Huiyu Deng, Zahra Eftekhari, Cameron Carlin, J. Veerapong, Keith F. Fournier, Fabian M. Johnston, S. Dineen, Benjamin D. Powers, Ryan Hendrix, Laura A. Lambert, Daniel E. Abbott, Kara Vande Walle, T. Grotz, Sameer H. Patel, C. Clarke, Charles A. Staley, S. Abdel-Misih, Jordan M. Cloyd, Byrne Lee, Yuman Fong, M. Raoof   +20 more
semanticscholar   +1 more source

The efficacy of cytoreductive surgery for oligometastatic prostate cancer: a meta-analysis

World Journal of Surgical Oncology, 2021
Backgrounds At present, the application of tumor reduction surgery in oligometastatic prostate cancer has aroused extensive discussion among urologists, but clinicians have not reached a consensus on this issue.
Bisheng Cheng, Shuchao Ye, Peiming Bai
doaj   +1 more source

Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01)

Journal of Gynecologic Oncology, 2022
Objective To investigate the health-related quality of life (HRQOL) related to hyperthermic intraperitoneal chemotherapy (HIPEC) following primary or interval cytoreductive surgery for primary ovarian cancer. Methods Between 2010 and 2016, a total of 184
J. Kim, Dong-eun Lee, Yumi Lee, H. I. Ha, Y. Chang, Suk-Joon Chang, Sang-Yoon Park, M. Lim   +7 more
semanticscholar   +1 more source

Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique

BMC Surgery, 2021
Background This study investigated the feasibility and safety of laparoscopic splenectomy conducted in the contexts of both laparoscopic secondary surgery for isolated recurrence in the spleen and primary laparoscopic cytoreductive surgery for advanced ...
Antonio Macciò, Elisabetta Sanna, Fabrizio Lavra, Giacomo Chiappe, Marco Petrillo, Clelia Madeddu   +5 more
doaj   +1 more source